A retrospective study evaluated the effectiveness of immunotherapy in patients with EGFR-mutated NSCLC by assessing both PD-L1 expression and TME parameters, including numbers of CD8+ TILs [57]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.